Fordeling (14C) - lenalidomids binding til plasmaproteiner in vitro var lav med gennemsnitlig plasmaproteinbinding på 22, 7% og 29, 2% hos henholdsvis patienter med myelomatose og raske forsøgspersoner.
Distribution In vitro (14C)-lenalidomide binding to plasma proteins was low with mean plasma protein binding at 22.7% and 29.2% in multiple myeloma patients and healthy volunteers, respectively.